Cardiovascular Complications of Pan-Cancer Therapies: The Need for Cardio-Oncology

Abstract

It is more likely that a long-term survivor will have both cardiovascular disease and cancer on account of the progress in cancer therapy. Cardiotoxicity is a well-recognized and highly concerning adverse effect of cancer therapies. This side effect can manifest in a proportion of cancer patients and may lead to the discontinuation of potentially life-saving anticancer treatment regimens. Consequently, this discontinuation may adversely affect the patient’s survival prognosis. There are various underlying mechanisms by which each anticancer treatment affects the cardiovascular system. Similarly, the incidence of cardiovascular events varies with different protocols for malignant tumors. In the future, comprehensive cardiovascular risk assessment and clinical monitoring should be considered for cancer treatments. Baseline cardiovascular evaluation risk should be emphasized prior to initiating clinical therapy in patients. Additionally, we highlight that there is a need for cardio-oncology to avoid or prevent cardiovascular side effects. Cardio-oncology service is based on identifying cardiotoxicity, developing strategies to reduce these toxicities, and minimizing long-term cardiotoxic effects.

Emerging cancer in individuals with cardiovascular disease: Exploring the intersection of reverse cardio-oncology and nephropharmacology

“…Otherwise, myocarditis could have occurred after infiltrating the inflammatory cells into the myocardium. Therefore, cardio-oncology is designed to assess and treat cardiotoxicity initiated by anticancer agents (9). complications in patients under chemotherapy.…”

Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer

“…Conversely, patients with endometrial cancer showed a very high risk of dying from CVDs at the first year after diagnosis, which remains elevated compared to other cancer sites [ 9 ]. Cardiotoxicity, in turn, is a recognized side effect of anticancer treatments that can ultimately lead to therapy discontinuation in some oncological patients [ 10 – 12 ].…”

Application of New Molecular Probes in the Diagnosis and Treatment of Malignant Tumors

“…Furthermore, an examination of recent research elucidating the involvement of WT1-associated protein (WTAP) in oncogenesis and its potential therapeutic implications was undertaken [11]. Another article reviews the current epidemiology and mechanisms of cardiac toxicity in pan-cancer therapies, stressing the importance of assessing relevant risk factors [12].…”